(12) Patent Application Publication (10) Pub. No.: US 2011/0014248 A1 Castiel Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2011/0014248 A1 Castiel Et Al US 2011 0014248A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0014248 A1 Castiel et al. (43) Pub. Date: Jan. 20, 2011 (54) COSMETIC USE OF MICROORGANISM(S) Publication Classification FOR THE TREATMENT OF SCALP (51) Int. Cl. DSORDERS A6IR 8/02 (2006.01) 46R 8/99 (2006.01) (75) Inventors: Isabelle Castiel, Nice (FR): A6II 35/74 (2006.01) Audrey Gueniche, Rueil A69/68 (2006.01) Malmaison (FR) A6IR 9/00 (2006.01) A69/48 (2006.01) Correspondence Address: A6IR 9/28 (2006.01) OBLON, SPIVAK, MCCLELLAND MAIER & A6IP 7/4 (2006.01) NEUSTADT, L.L.P. A61O 5/02 (2006.01) 194O DUKE STREET A61O 5/06 (2006.01) ALEXANDRIA, VA 22314 (US) A61O 5/10 (2006.01) A61O 5/12 (2006.01) (73) Assignees: LOREAL, Paris (FR); NESTEC A61O II/00 (2006.01) SA, Vevey (CH) (52) U.S. Cl. ..................... 424/401; 424/93.45; 424/93.4: 424/93.3; 424/93.44; 424/93.51; 424/93.46; (21) Appl. No.: 12/659,597 424/48; 424/439: 424/484; 424/456; 424/474; (22) Filed: Mar. 15, 2010 424/50: 424/70.1; 424/70.6 (57) ABSTRACT Related U.S. Application Data The present invention relates to a use of an effective amount (63) Continuation of application No. 12/509,756, filed on of at least one probiotic microorganism and/or a fraction Jul. 27, 2009, now abandoned. thereof and/or a metabolite thereof for preventing and/or treating dandruff disorders of the scalp, as well as a cosmetic (60) Provisional application No. 61/084,582, filed on Jul. process for preventing and/or treating a dandruff condition 29, 2008, provisional application No. 61/213,517, including the administration a first cosmetic active agent and filed on Jun. 16, 2009. of at least a second cosmetic active agent, topically, the said first and second cosmetic active agents being formulated in (30) Foreign Application Priority Data separate compositions, the first cosmetic active agent being chosen from probiotic microorganisms, and mixtures thereof, Nov. 19, 2008 (FR) ...................................... 08 57865 and the second cosmetic active agent being chosen from Jun. 2, 2009 (FR) ...................................... O953611 antidandruff active agents. Patent Application Publication Jan. 20, 2011 Sheet 1 of 4 US 2011/0014248A1 Rando 12 IA IB D1 D15 D29 D43 D57 D64 TIME Fig. 1 Patent Application Publication Jan. 20, 2011 Sheet 2 of 4 US 2011/0014248 A1 Rando I A 12 b IB D1 D15 D29 D43 D57 D64 TIME Fig.2 Patent Application Publication Jan. 20, 2011 Sheet 3 of 4 US 2011/0014248 A1 Rando IA 8 IB 6 4. D1 D15 D29 D43 D5, D64 TIME Fig. 3 Patent Application Publication Jan. 20, 2011 Sheet 4 of 4 US 2011/0014248 A1 Rando IA 1,80 I B S 1.50 : 120 s 0.90 0.60 0.30 D1 D15 D29 D43 D57 D64 TIME Fig. 4 US 2011/0014248 A1 Jan. 20, 2011 COSMETIC USE OF MICROORGANISM(S) sensations of itching or pruritus, resulting in scratching FOR THE TREATMENT OF SCALP behaviour which amplifies the phenomenon of appearance of DISORDERS the dandruff. 0009. The dandruff conditions of the scalp may be of CROSS REFERENCE TO RELATED greasy or oily type or of dry type. APPLICATIONS 0010. The dry dandruff conditions of the scalp are more 0001. This application claims priority to French Patent frequently manifested and are amplified during skin hydra Applications No. 08 57865, filed Nov. 19, 2008, and No. 09 tion disorders, and especially during Substantial dryness of 53611, filed Jun. 2, 2009, and U.S. Provisional Patent Appli the epidermis of the scalp. Thus, the treatment of dry dandruff cations No. 61/084,582, filed Jul. 27, 2008, and No. 61/213, conditions, and the Solving of the unattractive manifestations 217, filed Jun. 16, 2009, the disclosures of which are incor thereof, involve being able to sufficiently rehydrate the scalp. porated herein by reference in their entireties. 0011 Besides, as indicated above, the scalp is rich in BACKGROUND OF THE INVENTION sebaceous glands. It has been observed that dandruff develops more easily in the excessive presence of sebum and is more 0002 1. Field of the Invention readily pruritic. Sebum secretion is a normal phenomenon 0003. The present invention aims principally to propose a which is useful for the skin and for the head of hair. Sebum new active agent for the prevention and/or treatment of scalp protects the scalp and gives the haira sheen by lubricating the disorders, especially aesthetic disorders. In particular, the cuticle. However, hypersecretion of sebum, or seborrhoea, present invention relates to dandruff disorders of the scalp, in may lead to disruptions, annoyances, sensations or feelings of particular of a greasy scalp. The present invention is also discomfort, aesthetic disorders, or even a skin pathology. directed towards proposing a novel cosmetic process for pre Thus, an excessive secretion of sebum promotes the appear venting and/or treating a dandruff condition of the scalp. The ance of a greasy or oily dandruff condition of the scalp or present invention also relates to an assembly or kit that is greasy or oily dandruff. suitable for use in a process of the invention. The present 0012. It has also been recently demonstrated that yeast of invention also relates to the field of topical products, food Malassezia type have a Substantial lipase activity, resulting in Supplements or functional foods intended for Scalp care. the hydrolysis of sebum triglycerides so as to give fatty acids. 0004 2. Discussion of the Background These fatty acids are then capable of causing dandruff condi 0005. The scalp is an epidermis that undergoes continual tions in sensitive individuals, i.e. individuals having an renewal, like the rest of the cutaneous tissue, and that is rich impaired barrier function, and therefore more particularly in Sebaceous glands. Normally, the scalp is renewed by susceptible to the destructive action of fatty acids on the imperceptible, non-visible elimination of the superficial skin cutaneous barrier. cells. However, excessive renewal of the cells of the stratum 0013 Thus, the greater the presence of sebum, the more corneum of the scalp, for various reasons, may result in the readily oily dandruff develops. Moreover, it has a tendency to formation of large, thick patches of cells which are visible to be more readily pruritic. the naked eye, known as "dandruff. 0006 Various factors may promote the onset of dandruff. 0014 Dandruff conditions generally respond to various For example, mention may be made of stress, the winter local or systemic treatments. For example, various prepara period, an excess of sebum, a hydration defect or colonization tions comprising antimicrobial agents or keratolytic agents or of the skin or of the hair follicles by yeasts of the Malassezia keratinization regulators are commonly proposed for treating spp. type. These factors especially have the common feature dandruff conditions. In particular, preparations combining of causing or promoting skin inflammation. Such an inflam antifungal and anti-seborrhoeic agents have been proposed in mation reinforces the appearance or even increases the pres order to treat severe dandruff conditions, in particular greasy ence of dandruff. or oily dandruff conditions. The antifungal-based treatments 0007. The Malassezia sp. genus is constituted of lipophilic demonstrate certain effectiveness on oily dandruff condi yeast normally present on human skin and on the skin of tions. certain warm-blooded animals. The distribution thereof 0015. However, the efficacy of these treatments is only depends on age, on Sebaceous gland activity and on certain Suspensory and demands rigorous adherence on the part of pathologies. The Malassezia sp. yeast represents approxi the user (frequency of use and Sufficient application time). mately 45% of the normal commensal flora at the surface of Now, daily and long-term use of these treatments may lead to the scalp in individuals without dandruff, but can represent a phenomenon of dependence that reduces their efficacy. The 75% of the flora in the case of dandruff, and up to 85% in the dependence may be associated with a rebound phenomenon case of associated seborrhoeic dermatitis. The other microor occurring when the treatment is stopped. The rebound phe ganisms present at the Surface of the scalp are micrococci and nomenon is generally manifested by hyperseborrhoea or pru Propionobacterium. Imbalance of the scalp ecoflora is a fac ritus, which are paradoxically liable to worsen the dandruff tor that promotes or even reinforces the presence of dandruff. condition by impairing the barrier function of the scalp. 0008 Dandruff conditions are chronic, frequent, recurring 0016. Moreover, the aggressiveness of certain antidan conditions that are socially incapacitating Owing to their obvi druff active agents with respect to the epidermal cells or the ous unattractive nature. Many factors can amplify these phe Scalp ecoflora may also affect the scalp's barrier functions and nomena and result in the appearance of additional disorders, lead to worsening of the dandruff condition. Such as inflammatory conditions of the scalp. These dandruff 0017. Unpleasant side effects, such as heating or irritation conditions and/or inflammatory conditions of the scalp are phenomena, may also be manifested during the use of these reflected by an impairment of the barrier function of the treatments. These side effects may also be reflected by poor epidermis. What is more, these conditions may give rise to adherence to the treatments, thus reducing their efficacy. US 2011/0014248 A1 Jan. 20, 2011 0018. In addition, most of the active agents usually used 0035 Finally, there is still a need for a treatment for dan for treating dandruff often have an unpleasant odour that also druff conditions that is efficient and simple, and that can be reduces the adherence to the treatment.
Recommended publications
  • Pharmaceutical Sciences
    IAJPS 2017, 4 (08), 2671 - 2680 V.L.Sravani et al ISSN 2349 - 7750 CODEN [USA]: IAJPBB ISSN: 2349 - 7750 I N D O A M E R I C A N J O U R N A L O F P H A R M A C E U T I C A L S C I E N C E S Available online at: http://www.iajps.com Research Article ANTI - ACNE ACTIVITY OF LIPIDO - STEROLIC EXTRACT OF SERENOA REPENS AND HYDRO - ALCOHOLIC EXTRACT OF GLYCYRRHIZA GLABRA IN SYRIAN HAMSTER EAR MODEL V. Laxmi Sravani 1 *, Dr. B. Ch a n drasekhar Rao 1 , Dr. D. Ravi Krishna Babu 2 1 Department of Pharma cology, RGR Siddhanthi College of Pharmacy , Secundera bad. 2 Aurigene Discovery Technologies Pvt Ltd. Miyapur, Hyderabad. Abstract : Acne vulgaris is the most commonly encountered dermatological disease of pilosebaceous unit. Androgens, which increase during puberty, stimulate the sebaceous gland to produce sebum and cause retention of keratinocytes around the sebaceous hair follicle orifice causing partial to complete blockage and leading to colonization with Propionibacterium acnes, which participates in the production of pro inflammatory mediators. For treatment of acne one of the approaches is to reduce sebum production, the main stimulus to acne; then all other pathogenic factors will diminish. A comprehensive approach combining the natural medicine with anti - androgenic activity would be fruitful area for anti - acne therapy. In this context the well documented anti - androgenic herbs like liquorice and saw palmetto were selected and screened in Syrian hamster ear model using spironolactone as standard.
    [Show full text]
  • Consolidated Version of the Sanpin 2.3.2.1078-01 on Food, Raw Material, and Foodstuff
    Registered with the Ministry of Justice of the RF, March 22, 2002 No. 3326 MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION CHIEF STATE SANITARY INSPECTOR OF THE RUSSIAN FEDERATION RESOLUTION No. 36 November 14, 2001 ON ENACTMENT OF SANITARY RULES (as amended by Amendments No.1, approved by Resolution No. 27 of Chief State Sanitary Inspector of the RF dated 20.08.2002, Amendments and Additions No. 2, approved by Resolution No. 41 of Chief State Sanitary Inspector of the RF dated15.04.2003, No. 5, approved by Resolution No. 42 of Chief State Sanitary Inspector of the RF dated 25.06.2007, No. 6, approved by Resolution No. 13 of Chief State Sanitary Inspector of the RF dated 18.02.2008, No. 7, approved by Resolution No. 17 of Chief State Sanitary Inspector of the RF dated 05.03.2008, No. 8, approved by Resolution No. 26 of Chief State Sanitary Inspector of the RF dated 21.04.2008, No. 9, approved by Resolution No. 30 of Chief State Sanitary Inspector of the RF dated 23.05.2008, No. 10, approved by Resolution No. 43 of Chief State Sanitary Inspector of the RF dated 16.07.2008, Amendments No.11, approved by Resolution No. 56 of Chief State Sanitary Inspector of the RF dated 01.10.2008, No. 12, approved by Resolution No. 58 of Chief State Sanitary Inspector of the RF dated 10.10.2008, Amendment No. 13, approved by Resolution No. 69 of Chief State Sanitary Inspector of the RF dated 11.12.2008, Amendments No.14, approved by Resolution No.
    [Show full text]
  • THE BARRON REPORT Volume 7, Issue 6 © 1999, Jon Barron
    THE BARRON REPORT Volume 7, Issue 6 © 1999, Jon Barron. All Rights Reserved. Health For Every Man Over 30 The Prostate Problem Like women, men too are exposed to the effects of chemical estrogens in their environment. In addition, as their testosterone levels drop with age, there is, in many cases, a concomitant rise in estradiol levels -- the major reason that many older men develop breasts. Just as with women, estradiol stimulates cell growth in men too and is potentially cancerous. Estradiol stimulates the BCL2 gene, which is the gene responsible for stopping cell death. What at first glance sounds like a positive, is, upon closer inspection, not. When cell death in prostate tissue, for example, is blocked, cell growth continues unabated -- becoming a major contributing factor in the enlargement of the prostate and the development of prostate cancer. This is one of the main factors involved in the dramatically increased incidence of prostate cancer. • A new case of Prostate Cancer is diagnosed every 3 minutes in America and every 15 minutes a man dies from prostate cancer. • Prostate Cancer is the second leading type of cancer among men. • 11 million men have some form of Prostate Cancer in the United States. • African-American men have the highest rate of Prostate Cancer in the world. • Survival rates for men with prostate cancer in 1995 were no different than they were in 1965. • The age at which Prostate Cancer develops will drop ten years by the year 2000. By the year 2000, Prostate Cancer will increase by 90%. The Prostate Solution Regular use of a men's progesterone crememakes a great deal of sense for any man over the age of 30.
    [Show full text]
  • WO 2013/116261 A2 8 August 2013 (08.08.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/116261 A2 8 August 2013 (08.08.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every CUD 3/386 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2013/023728 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 30 January 2013 (30.01 .2013) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 12000745.5 3 February 2012 (03.02.2012) EP 12001034.3 16 February 2012 (16.02.2012) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: THE PROCTER & GAMBLE COMPANY GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, [US/US]; One Procter & Gamble Plaza, Cincinnati, Ohio UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 45202 (US).
    [Show full text]
  • Super Greens
    SUPER GREENS SUPPLEMENT FACTS Serving Size: 1 Scoop (10 g) Servings Per Container: 30 Amount Per Serving % Daily Value Calories 25 Total Carbohydrate 6 g 2%* Dietary Fiber 3 g 12%* Sugars 1 g † Protein <1 g <2%* Organic Super Greens, Sprouts & Prebiotic Fiber Blend: 3.5 g Wheat grass, barley grass, spirulina (blue green algae), green pea fiber, oat fiber, flaxseed, blue agave inulin, plum, orange peel, apple fiber, lemon peel, kale, broccoli, spinach, parsley, green cabbage, alfalfa grass, chlorella, green tea, tomato, sweet potato, pumpkin, dandelion root, collard greens, dulse, adzuki sprout, amaranth sprout, buckwheat sprout, chia sprout, flax sprout, garbanzo bean sprout, lentil bean sprout, millet sprout, pumpkin sprout, quinoa sprout, sesame sprout, sunflower sprout Organic Super Foods & Fruits Blend: 3.5 g Beet root, carrot, Organic Berry Blend [acai berry (Euterpe oleracea), apple, banana, bilberry, black currant, blueberry, cherry, elderberry, goji berry (Lycium barbarum), grape, maqui berry (Aristotelia chilensis), papaya, pineapple, pomegranate, raspberry, strawberry], apple, shitake mushroom, reishi mushroom, maitake mushroom, blueberry, raspberry, strawberry, peach, blackberry, lemon, pear, cranberry, grape, pomegranate, cherry, orange Probiotic Blend: 500 million CFU Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus casei, Streptococcus thermophilus * Percent Daily Values are based on a 2,000 calorie diet. † Daily value not established. Other ingredients: Organic tapioca starch, organic guar gum, citric acid, organic natural berry flavor and organic rebaudioside A. .
    [Show full text]
  • AFS – Advances in Food Sciences Continuation of CMTL Founded by F
    AFS – Advances in Food Sciences Continuation of CMTL founded by F. Drawert Production by PSP – Parlar Scientific Publications, Angerstr. 12, 85354 Freising, Germany in cooperation with Lehrstuhl für Chemisch-Technische Analyse und Lebensmitteltechnologie, Technische Universität München, 85350 Freising - Weihenstephan, Germany Copyright © by PSP – Parlar Scientific Publications, Angerstr. 12, 85354 Freising, Germany. All rights are reserved, especially the right to translate into foreign language. No part of the journal may be reproduced in any form- through photocopying, microfilming or other processes- or converted to a machine language, especially for data processing equipment- without the written permission of the publisher. The rights of reproduction by lecture, radio and television transmission, magnetic sound recording or similar means are also reserved. Printed in GERMANY – ISSN 14311431----77377737 © by PSP Volume 24 – No 4. 2002 Advances in Food Sciences 1 © by PSP Volume 24 – No 4. 2002 Advances in Food Sciences AFSAFS---- Editorial Board Chief Editors: Prof. Dr. H. Parlar Institut für Lebensmitteltechnologie und Analytische Chemie, TU München - 85350 Freising-Weihenstephan, Germany - E-mail: [email protected] Dr. G. Leupold Institut für Lebensmitteltechnologie und Analytische Chemie, TU München - 85350 Freising-Weihenstephan, Germany - E-mail: [email protected] CoCo----Editor:Editor: Prof. Dr. R. G. Berger Zentrum Angewandte Chemie, Institut für Lebensmittelchemie, Universität Hannover Wunstorfer Straße 14, 30453 Hannover - E-mail: [email protected] AFSAFS- Advisory Board E. Anklam, I M. Bahadir, D F. Coulston, USA J.M. de Man, CAN N. Fischer, D S. Gäb, D A. Görg, D U. Gill, CAN D. Hainzl, P W.P. Hammes, D D. Kotzias, I F.
    [Show full text]
  • Public Health Impact a Suitable Test for L-Citrulline—
    1 Winter 2016 Public Health Impact A Suitable Test for L-citrulline— How Validated Test Methods May New Dietary Supplements Impact Public Health Reference Standards In the U.S., most newborn babies are screened for rare inborn errors of Below is a list of newly released metabolism (IEM)—a group of genetic disorders caused by a defect in a reference standards: metabolic pathway. Left untreated, these disorders can lead to a host of Botanicals medical and developmental consequences ranging from intellectual 1 disability to severe cognitive impairment and even death. • 2,3,5,4’-Tetrahydroxystilbebe-2- Some of these metabolic errors require the use of amino acids to avoid O-Beta-D-Glucoside the buildup of ammonia in the body. L-citrulline is one such amino acid, • Emodin and it is used for IEM as a medical food, which is regulated by the U.S. Food and Drug Administration (FDA) under the Orphan Drug Act. Medical • Polygonum multiflorum Root Dry foods are distinct within the broader category of foods and need to be Extract administered under the supervision of a healthcare professional • Lonicera japonica Flower Dry specifically to help manage a disease or condition associated with Extract distinctive nutritional requirements. In addition to being marketed as a medical food for IEM, L-citrulline is marketed as a dietary supplement for • Secoxyloganin other purposes. • Lonicera macranthoides Flower Sometimes, the quality control testing done to authenticate ingredients is Dry Extract insufficient to guarantee their quality. That was the case with L-citrulline in Luteolin-7-O-glucoside 2014. • One of the primary suppliers of the ingredient for use as a medical food voluntarily recalled several batches of the product after the FDA warned Non-Botanicals that the product being sold had no L-citrulline present.
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • The 5ARI Withdrawal Syndrome (5ARI-WS)
    The 5ARI Withdrawal Syndrome (5ARI-WS) The Silenced Androgen Receptor (AR) Theory: Explaining persistent side effects arising from 5alpha reductase (5AR) inhibitor (5ARI) use By “Awor” and “Mew”, Administrators of Propeciahelp.com (July 2010) 1. Introduction An increasingly overwhelming amount of evidence is starting to accumulate from various doctors, scientists, patient groups and online discussion forums, whereby seemingly unrelated substances such as finasteride, dutasteride, isotretinoin and saw palmetto extract (SPE) based preparations are causing young consumers to suffer from long-term, irreversible and serious health damage. The experienced persistent side effect have a clear denominator in that they all seem to relate to physiological and psychological functions which require androgens to function correctly: Loss of libido (1) (2) Low energy, fatigue (1) Depression (including suicidal depression)* (3) (4) (5) (6) Impaired thought processes* (7) Memory failure* (7) Erectile dysfunction (8) (9) (2) Penile atrophy (9) Impaired spermatogenesis (10) (11) (12) Muscle wasting (13) (14) (15) Gynecomastia (16) Dry skin and dry eyes (17) (18) (19) Prostate problems (2) Metabolic syndrome (20) Osteoporosis (21) (22) Anxiety and sleep disorders, muscle spasms (23) (24) (25) * Indirect action through 3α-HSD as described later in this document Of substantial note is that most side effects typically surface or reach full extent roughly 10-14 days after quitting the 5ARI substances. Androgen dependent tissue atrophy (penile, scrotum,
    [Show full text]
  • Potential Use of Bacillus Coagulans in the Food Industry
    foods Review Potential Use of Bacillus coagulans in the Food Industry Gözde Konuray * ID and Zerrin Erginkaya ID Department of Food Engineering, Cukurova University, Adana 01330, Turkey; [email protected] * Correspondence: [email protected]; Tel.: +90-322-338-60-84 Received: 1 May 2018; Accepted: 11 June 2018; Published: 13 June 2018 Abstract: Probiotic microorganisms are generally considered to beneficially affect host health when used in adequate amounts. Although generally used in dairy products, they are also widely used in various commercial food products such as fermented meats, cereals, baby foods, fruit juices, and ice creams. Among lactic acid bacteria, Lactobacillus and Bifidobacterium are the most commonly used bacteria in probiotic foods, but they are not resistant to heat treatment. Probiotic food diversity is expected to be greater with the use of probiotics, which are resistant to heat treatment and gastrointestinal system conditions. Bacillus coagulans (B. coagulans) has recently attracted the attention of researchers and food manufacturers, as it exhibits characteristics of both the Bacillus and Lactobacillus genera. B. coagulans is a spore-forming bacterium which is resistant to high temperatures with its probiotic activity. In addition, a large number of studies have been carried out on the low-cost microbial production of industrially valuable products such as lactic acid and various enzymes of B. coagulans which have been used in food production. In this review, the importance of B. coagulans in food industry is discussed. Moreover, some studies on B. coagulans products and the use of B. coagulans as a probiotic in food products are summarized. Keywords: Bacillus coagulans; probiotic; microbial enzyme 1.
    [Show full text]
  • Isolation and Characterization of Probiotic Bacillus Subtilis MKHJ 1-1 Possessing L-Asparaginase Activity
    applied sciences Article Isolation and Characterization of Probiotic Bacillus subtilis MKHJ 1-1 Possessing L-Asparaginase Activity Hyeji Lim 1 , Sujin Oh 1 , Sungryul Yu 2 and Misook Kim 1,* 1 Department of Food Science and Nutrition, Dankook University, Cheonan 31116, Korea; [email protected] (H.L.); [email protected] (S.O.) 2 Department of Clinical Laboratory Science, Semyung University, Jecheon 27136, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-41-550-3494 Abstract: The purpose of this study was to isolate functional Bacillus strains from Korean fermented soybeans and to evaluate their potential as probiotics. The L-asparaginase activity of MKHJ 1-1 was the highest among 162 Bacillus strains. This strain showed nonhemolysis and did not produce β-glucuronidase. Among the nine target bacteria, MKHJ 1-1 inhibited the growth of Escherichia coli, Pseudomonas aeruginosa, Shigella sonnei, Shigella flexneri, Klebsiella pneumoniae, Staphylococcus aureus, and Bacillus cereus. 16S rRNA gene sequence analysis resulted in MKHJ 1-1 identified as Bacillus subtilis subsp. stercoris D7XPN1. As a result of measuring the survival rate in 0.1% pepsin solution (pH 2.5) and 0.3% bile salt solution for 3 h, MKHJ 1-1 exhibited high acid resistance and was able to grow in the presence of bile salt. MKHJ 1-1 showed outstanding autoaggregation ability after 24 h. In addition, its coaggregation with pathogens was strong. Therefore, MKHJ 1-1 is a potential probiotic with L-asparaginase activity and without L-glutaminase activity, suggesting that it could be a new resource for use in the food and pharmaceutical industry.
    [Show full text]
  • Beta-Sitosterol [BSS] and Betasitosterol Glucoside [BSSG] As an Adjuvant in the Treatment of Pulmonary Tuberculosis Patients.” TB Weekly (4 Mar 1996)
    Saw Palmetto (Serenoa repens) and One of Its Constituent Sterols -Sitosterol [83-46-5] Review of Toxicological Literature Prepared for Errol Zeiger, Ph.D. National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, North Carolina 27709 Contract No. N01-ES-65402 Submitted by Raymond Tice, Ph.D. Integrated Laboratory Systems P.O. Box 13501 Research Triangle Park, North Carolina 27709 November 1997 EXECUTIVE SUMMARY The nomination of saw palmetto and -sitosterol for testing is based on the potential for human exposure and the limited amount of toxicity and carcinogenicity data. Saw palmetto (Serenoa repens), a member of the palm family Arecaceae, is native to the West Indies and the Atlantic Coast of North America, from South Carolina to Florida. The plant may grow to a height of 20 feet (6.10 m), with leaves up to 3 feet (0.914 m) across. The berries are fleshy, about 0.75 inch (1.9 cm) in diameter, and blue-black in color. Saw palmetto berries contain sterols and lipids, including relatively high concentrations of free and bound sitosterols. The following chemicals have been identified in the berries: anthranilic acid, capric acid, caproic acid, caprylic acid, - carotene, ferulic acid, mannitol, -sitosterol, -sitosterol-D-glucoside, linoleic acid, myristic acid, oleic acid, palmitic acid, 1-monolaurin and 1-monomyristin. A number of other common plants (e.g., basil, corn, soybean) also contain -sitosterol. Saw palmetto extract has become the sixth best-selling herbal dietary supplement in the United States. In Europe, several pharmaceutical companies sell saw palmetto-based over-the-counter (OTC) drugs for treating benign prostatic hyperplasia (BPH).
    [Show full text]